Because untreated aging leads to frailty, cardiovascular disease, brain disorders, and death, we need rejuvenation biotechnology to reverse the aging processes and thereby restore youth and health.
As explained on our What is Aging? page, aging consists of multiple processes (“hallmarks”) that gradually cause harm and lead to age-related disease. Most products marketed as “anti-aging” or that purport to “rejuvenate” the body do not actually address any of these hallmarks and cannot affect the root causes of age-related disease; therefore, they are not rejuvenation biotechnology.
Rejuvenation biotechnology is advanced medical technology that directly addresses any of the various aging processes in order to restore tissue and organ function to a more youthful state, thereby ameliorating, delaying, or preventing age-related diseases.
Ultimately, the goal of rejuvenation biotechnology is to make chronologically old and chronologically young people, at every physical level, indistinguishable from one another.
However, no single rejuvenative therapy will completely restore someone to a youthful state. Because the causes of aging are so broad and interlinked, rejuvenation biotechnology must be broad and comprehensive to match.
For example, senolytics are rejuvenative because they eliminate harmful senescent cells, which accumulate with age and are one of the hallmarks of aging. However, because types of senescent cells differ from one another, a comprehensive suite of senolytic therapies is required to directly address this particular hallmark through destroying these cells. Stem cell therapies are rejuvenative because they address stem cell exhaustion, restoring the body’s youthful ability to repair tissues; however, because the body requires many types of stem cells for long-term function, each stem cell niche must be replenished.
Because each hallmark requires intensive effort to comprehensively combat, it is clear that building a complete set of rejuvenation biotechnology therapies will require a great deal of research and development. Creating this technology will require help from investors, medical professionals, researchers, policymakers, and members of the public. Poor funding is one of the four bottlenecks of the development of rejuvenation biotechnology.